Severe Thrombocythemia

SAN DIEGO — Pacritinib may provide a “unique survival advantage” for patients with myelofibrosis also exhibiting moderate or severe thrombocythemia, according to data from the PERSIST-2 study, presented at ASH Annual Meeting and Exposition.